Luís Pacheco-Figueiredo1, Nuno Lunet. 1. Department of Clinical Epidemiology, Predictive Medicine and Public Health, Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.
Abstract
PURPOSE: Understanding the morbidity and socio-economic implications of cancer survivorship is essential for a comprehensive management of oncological diseases. We compared cancer survivors (CS) with the general population regarding health status, use of healthcare resources and socio-economic condition. METHODS: We analyzed data from a representative sample of the Portuguese population aged ≥15 years (n = 35,229). We defined three groups of CS, according to the time since diagnosis and the latest cancer treatment: CS 1 diagnosis within 12 months of interview; CS 2 diagnosis more than 12 months before and treatment in the previous 12 months; CS 3 diagnosis and treatment more than 12 months before. These were compared with the general population, adjusting for differences in sex, age, and place of residence. RESULTS: The prevalence of CS was 2.2% (CS 1: 0.2%; CS 2: 0.9%, CS 3: 1.1%). Self-perceived health status was worse among CS and short-time incapacity more frequent among CS 1 and CS 2. Health expenses were higher in the early stages of survivorship. Lower household income and financial difficulties were more frequent in CS 1 and CS 3 men, respectively. CONCLUSION: This study confirmed the higher consumption of healthcare resources and worse financial situation among CS. IMPLICATIONS FOR CANCER SURVIVORS: Our study provides valuable information for understanding the global impact of cancer survivorship.
PURPOSE: Understanding the morbidity and socio-economic implications of cancer survivorship is essential for a comprehensive management of oncological diseases. We compared cancer survivors (CS) with the general population regarding health status, use of healthcare resources and socio-economic condition. METHODS: We analyzed data from a representative sample of the Portuguese population aged ≥15 years (n = 35,229). We defined three groups of CS, according to the time since diagnosis and the latest cancer treatment: CS 1 diagnosis within 12 months of interview; CS 2 diagnosis more than 12 months before and treatment in the previous 12 months; CS 3 diagnosis and treatment more than 12 months before. These were compared with the general population, adjusting for differences in sex, age, and place of residence. RESULTS: The prevalence of CS was 2.2% (CS 1: 0.2%; CS 2: 0.9%, CS 3: 1.1%). Self-perceived health status was worse among CS and short-time incapacity more frequent among CS 1 and CS 2. Health expenses were higher in the early stages of survivorship. Lower household income and financial difficulties were more frequent in CS 1 and CS 3men, respectively. CONCLUSION: This study confirmed the higher consumption of healthcare resources and worse financial situation among CS. IMPLICATIONS FOR CANCER SURVIVORS: Our study provides valuable information for understanding the global impact of cancer survivorship.
Authors: Floortje Mols; Melissa S Y Thong; Pauline Vissers; Tamar Nijsten; Lonneke V van de Poll-Franse Journal: Eur J Cancer Date: 2011-12-21 Impact factor: 9.162
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: F Fontes; M Severo; C Castro; S Lourenço; S Gomes; F Botelho; C La Vecchia; N Lunet Journal: Br J Cancer Date: 2013-05-09 Impact factor: 7.640